Latest news with #Dr.Reddy
The Hindu
4 hours ago
- Business
- The Hindu
Dr. Reddy's Q1 net inches up amid decline in generics sales to U.S.
Generic drugmaker Dr. Reddy's Laboratories' consolidated net profit for the June quarter increased marginally to ₹1,409.9 crore from Rs.1,392.4 crore year earlier as revenue from the all important U.S. market declined amid increased price erosion in certain key products. The net profit came on a more than 11% increase in total revenue from operations to ₹.8,572.1 crore (₹.7,696.1 crore), the results prepared as per Indian Accounting Standards (Ind AS) showed. Pricing pressure on cancer drug Lenalidomide is expected to intensify in the U.S. generics market, according to co-chairman and MD G.V. Prasad. He said this reaffirming the company's focus on strengthening the base business by delivery of our pipeline assets, improving overall productivity and business development.' On segment revenue, the company said global generics contributed ₹7,573.2 crore (₹.6,892.9 crore), while share of Pharmaceutical Services and Active Ingredients declined to ₹987.4 crore (₹1,047.2 crore). In a release, on the results prepared as per International Financial Reporting Standards (IFRS), Dr. Reddy's said revenue from the North America generics market at ₹3,410 crore was 11% lower a decline YoY of and 4% QoQ. The decline was primarily due to increased price erosion in certain key products, including Lenalidomide. Revenue from generics sales in Europe, India and Emerging Markets were higher year on year. The company's shares closed less than 1% higher at ₹1,247.55 each on the BSE.
Hans India
5 hours ago
- Business
- Hans India
Dr. Reddy's Laboratories' net profit slumps 11 pc to Rs 14,09 crore sequentially in Q1
Mumbai: Dr. Reddy's Laboratories' net profit stood at Rs 1,409.6 crore in the first quarter of the current fiscal (Q1 FY26), down 11 per cent sequentially, the company said in an exchange filing on Wednesday. The company had reported a consolidated profit of Rs 1,587.3 crore in the preceding quarter (Q4 FY25). However, the profit of the Hyderabad-based firm saw a marginal jump of over a per cent on year-on-year (YoY) from Rs 1,392 crore in the same quarter a year ago, according to the filing. Meanwhile, Dr. Reddy's Labs revenue stood at Rs 8,545.2 crore in the quarter under review, up around Rs 40 crore sequentially from Rs 8,506 crore, and Rs 872.5 crore year-on-year (YoY) from Rs 7,672.7 crore. The pharmaceutical company saw a jump of Rs 153 crore in its total operating expenses this quarter QoQ, leading to a decline in its net profit. The company reported total operating expenses of Rs 3,115.2 crore in Q1 FY26 against Rs 2,961.6 crore in Q4 FY25. "We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio. The pricing pressure on Lenalidomide is expected to intensify in the U.S. generics market," said GV Prasad, Co-Chairman and MD. "We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development," Prasad added. Meanwhile, the company has expanded partnership with Alvotech to co-develop, manufacture and co-commercialise pembrolizumab, a biosimilar candidate, this quarter, as per the filing. It has also launched Sensimune in India, an immunotherapy product for house dust mite-induced allergies. The shares of the company closed in positive territory on Wednesday. The stock settled at Rs 1,248.0, up 0.65 per cent. Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad.
Business Upturn
5 days ago
- Business
- Business Upturn
Dr. Reddy's receives 7 observations from USFDA after inspection at Srikakulam plant
By Aditya Bhagchandani Published on July 18, 2025, 18:21 IST Dr. Reddy's Laboratories Ltd. announced on July 18 that the United States Food & Drug Administration (USFDA) has completed a Good Manufacturing Practice (GMP) and Pre-Approval Inspection (PAI) at its formulations manufacturing facility FTO 11, located in Srikakulam, Andhra Pradesh. According to the company's filing with stock exchanges, the inspection was conducted over eight days, from July 10 to July 18, 2025. At the conclusion of the inspection, the USFDA issued a Form 483 with seven observations. Dr. Reddy's stated that it would address the observations within the stipulated timeline, as per regulatory requirements. The company said the disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and is meant for public record and investor information. The Hyderabad-headquartered pharmaceutical major operates several manufacturing facilities in India and abroad, and this development comes as part of its routine regulatory inspections for ongoing compliance and product approvals. Disclaimer: This information is based solely on the company's official disclosure dated July 18, 2025. Business Upturn or the author is not liable for any actions taken based on this information. Investors are advised to independently verify and consult financial advisors before making investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Economic Times
09-07-2025
- Business
- Economic Times
Stock Market LIVE Updates: GIFT Nifty signals a negative start; Asian shares trade mixed
Sensex Today | Stock Market LIVE Updates: Indian equities ended marginally higher on Tuesday, with the Nifty settling at 25,522. Analysts remain upbeat about near-term market prospects, driven by expectations of a trade breakthrough and the upcoming earnings season. The BSE Sensex rose by 270.01 points, or 0.32%, ending at 83,712.51, while the NSE Nifty gained 61.20 points, or 0.24%, to close at 25,522.50. Sensex Today | Stock Market LIVE Updates: Indian benchmark indices are likely to get off to a negative start on Wednesday after settling slightly higher in the previous session. The Nifty closed at 25,222 on Tuesday, supported by hopes of a trade breakthrough and optimism ahead of the upcoming earnings season. Sensex Today | Stock Market LIVE Updates: Dr. Reddy's shares to turn ex-dividend tomorrow — last chance to buy today Dr. Reddy's Laboratories shares are in the spotlight on Wednesday, July 9, as today is the last day to purchase the stock to be eligible for the final dividend of ₹8 per share for FY24. The stock will trade ex-dividend starting tomorrow. Sensex Today | Stock Market LIVE Updates:Investors turn to money market funds as interest rates decline With interest rates on a downward trajectory and growing caution around traditional fixed-income instruments, money market funds have become a favoured choice for short-term investors. These funds are witnessing strong inflows, with AMFI data showing nearly ₹43,000 crore pouring in during April and May 2025—making them the second-highest contributor among 16 debt fund categories. Read more Stock Market LIVE Updates: Copper prices slip as Trump announces steep 50% import tariff Copper prices declined on Wednesday after U.S. President Donald Trump abruptly announced a 50% import tariff on copper. Three-month copper on the London Metal Exchange (LME) dropped 0.57% to $9,735 per metric ton by 0109 GMT, while the most-traded copper contract on the Shanghai Futures Exchange (SHFE) fell 0.49% to 79,090 yuan per ton. Sensex Today | Stock Market LIVE Updates: India's insurance sector sees muted Q1 FY26 growth amid regulatory hurdles, weak demand India's insurance industry posted subdued growth in the June quarter of FY26, weighed down by differing headwinds across life and non-life segments. Analysts attribute the tepid performance in the life insurance space to regulatory changes and a high base effect. Read more Sensex Today | Stock Market LIVE Updates: Ex-SEBI chief Madhabi Buch refutes regulatory failure claims in Jane Street case Former SEBI Chairperson Madhabi Puri Buch has dismissed allegations of regulatory failure in the Jane Street case, calling such claims a 'false narrative.' She clarified that SEBI had detected index manipulation by Jane Street and had taken multiple actions between April 2024 and February 2025. Read more Sensex Today | Stock Market LIVE Updates: Asston Pharmaceuticals IPO opens today, price band set at ₹115–123 The initial public offering of Asston Pharmaceuticals, a rapidly expanding exporter of healthcare and pharmaceutical products, opens for subscription today. The book-built issue is priced in the range of ₹115 to ₹123 per share, with a fixed lot size of 1,000 shares. Read more Sensex Today | Stock Market LIVE Updates: Crizac shares set to debut today after successful IPO Crizac, a B2B education platform focused on international student recruitment, is scheduled to list on the stock exchanges today, July 9, following a stellar IPO response. The ₹860 crore offer, comprised entirely of an offer-for-sale (OFS), was subscribed 63 times. Read more Sensex Today | Stock Market LIVE Updates: Oil dips from two-week highs amid tariff uncertainty Oil prices slipped slightly on Wednesday, pulling back from two-week highs reached in the previous session, as investors awaited clarity on U.S. trade policy and its potential impact on demand. Brent crude futures eased 20 cents, or 0.3%, to $69.95 a barrel by 0121 GMT. Read more Stock Market LIVE Updates: Gold inches up as Trump's tariff threats weigh on trade optimism Gold prices edged higher on Wednesday as renewed tariff threats from U.S. President Donald Trump dampened hopes for progress in trade negotiations. However, gains were limited by a stronger dollar and rising U.S. Treasury yields. Spot gold was up 0.2% at $3,305.50 per ounce as of 0106 GMT. Read more Sensex Today | Stock Market LIVE Updates: Asian stocks cautious as Trump's tariff stance dents sentiment Asian markets opened mixed on Wednesday, with investors turning risk-averse after President Donald Trump ruled out extending the August tariff deadline. Japan's shares gained, while Australia declined, and the broader Asian index dipped 0.1%. Copper futures fell in London following Trump's plan to impose a 50% import tariff. Read more Sensex Today | Stock Market LIVE Updates: Dollar strengthens vs yen as Trump ramps up trade war rhetoric The U.S. dollar climbed for a third straight day against the yen on Wednesday, buoyed by escalating trade tensions after President Donald Trump vowed further trade-related actions. Read more Sensex Today | Stock Market LIVE Updates: Forex news The euro was little changed at $1.1724 The Japanese yen fell 0.1% to 146.77 per dollar The offshore yuan was little changed at 7.1824 per dollar Sensex Today | Stock Market LIVE Updates: Global market update S&P 500 futures fell 0.1% as of 10:39 a.m. Tokyo time Japan's Topix rose 0.2% Australia's S&P/ASX 200 fell 0.4% Hong Kong's Hang Seng fell 0.7% The Shanghai Composite rose 0.2% Euro Stoxx 50 futures rose 0.2% Stock Market LIVE Updates: Wall Street slips as investors await tariff clarity U.S. stocks closed slightly lower on Tuesday in a volatile session, as investors remained cautious amid uncertainty over U.S. trade policy. Fresh tariff threats from President Donald Trump clouded optimism surrounding trade negotiations with key partners. Read more Stock Market LIVE Updates: Gold ETFs see biggest H1 inflows since 2020: WGC Physically backed gold exchange-traded funds attracted their highest first-half inflows since 2020, from January to June 2025, according to data released by the World Gold Council on Tuesday. The surge marks the strongest semi-annual demand for gold ETFs in five years. Read more Stock Market LIVE Updates: Euro zone bond yields climb to six-week highs amid focus on auctions The absence of fresh U.S. tariffs on the European Union shifted investor attention to regional fiscal developments, including government spending and borrowing plans. Germany's 10-year bond yield — the euro zone benchmark — climbed 4 basis points to 2.64%, after hitting its highest level since May 21 earlier in the session. Read more Global Market LIVE Updates: Asian stocks cautious as tariff talk sinks copper Asian markets traded cautiously as investors responded to President Trump's uncompromising tariff stance, with no extensions in sight. Copper futures slipped amid renewed tariff threats, weighing on global metal sentiment. While there has been progress with the EU, the risk of fresh tariffs on U.S. tech firms lingers, keeping markets largely unmoved—unless economic data disappoints or inflation spikes. Sensex Today | Stock Market LIVE Updates: Stocks in news: Tata Steel, JSW Steel, KPI Green, Tata Motors, Union Bank In today's session, stocks like Tata Steel, JSW Steel, KPI Green, Tata Motors, and Union Bank will be in focus amid key news updates and Q1 earnings announcements. GIFT Nifty LIVE Updates: GIFT Nifty (Earlier SGX Nifty) signals a negative start GIFT Nifty on the NSE IX traded lower by 25 points, or 0.10 per cent, at 25,579, signaling that Dalal Street was headed for negative start on Wednesday. Sensex Today | Stock Market LIVE Updates: Ahead of Market: 10 things that will decide stock market action on Tuesday Indian equities ended higher on Tuesday, supported by gains in financial and IT stocks, following U.S. President Trump's decision to delay tariffs and growing optimism around a potential India–U.S. trade deal. Read more Sensex Today | Stock Market LIVE Updates: Sensex, Nifty on Tuesday Indian benchmark indices, Sensex and Nifty, closed higher on Tuesday, driven by gains in financial and IT stocks. The rally followed U.S. President Donald Trump's move to postpone new tariffs until August 1, while also imposing fresh duties on several trade partners. Read more
Economic Times
06-06-2025
- Business
- Economic Times
Dr. Reddy's shares rise over 1% on strategic collaboration with Alvotech for Keytruda Biosimilar
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Shares of Dr. Reddy's Laboratories rose 1.4% to touch the day's high of Rs 1,307.65 on the BSE on Friday, June 6, after the company announced a strategic collaboration with Alvotech , a global biotech firm, to co-develop and commercialize a biosimilar candidate to Keytruda ( pembrolizumab ) for global markets.'Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines, and Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as 'Dr. Reddy's'), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets,' Dr. Reddy's said in an exchange a leading immunotherapy drug used in the treatment of various cancers, generated $29.5 billion in global sales in 2024, making it one of the most valuable targets in the biosimilars partnership represents a significant opportunity for Dr. Reddy's to enter the high-value biosimilar segment for oncology drugs, a category that continues to witness growing demand and heightened competitive the agreement, both parties will jointly develop and manufacture the biosimilar, sharing costs and responsibilities. Importantly, each company will retain the right to commercialize the product globally, subject to certain deal is expected to accelerate development timelines and expand the global market reach of the biosimilar.Róbert Wessman, Chairman and CEO of Alvotech, emphasized that the agreement will help deliver cost-effective, critical biologic medicines to patients worldwide by combining Dr. Reddy's commercial strength with Alvotech's R&D and manufacturing this collaboration, Dr. Reddy's further strengthens its pipeline in the biosimilars segment.'We are pleased to collaborate with Alvotech on the pembrolizumab biosimilar. This demonstrates our ability to develop and manufacture high-quality, affordable treatment options for patients across the world. Oncology has been a key focus area for us, and this collaboration will enhance our capabilities in this domain, as pembrolizumab represents one of the most critical therapies in immuno-oncology,' said Erez Israeli, CEO of Dr. Reddy' Reddy's Laboratories shares ended Thursday's session higher by 3% at Rs 1,289.90 on BSE.
